Healios KKHLOSF 57 OCF Margin % is -16,006.00% as of Mar. 2026. GuruFocus rates HLOSF with a GF Score™ of 57/100 and a GF Value™ of $0.42 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 957 Biotechnology companies, Healios KK ranks worse than 90.91% on this metric.
The historical rank and industry rank for Healios KK's OCF Margin % or its related term are showing as below:
HLOSF'
s OCF Margin % Range Over the Past 10 Years
Min: -14611.11 Med: -5112.22 Max: -324.46
Current: -4916.53
During the past 12 years, the highest OCF Margin % of Healios KK was -324.46%. The lowest was -14611.11%. And the median was -5112.22%.
HLOSF's OCF Margin % is ranked worse than 90.91% of 957
companies
in the Biotechnology industry
Industry Median: -66.52
vs HLOSF: -4916.53
Healios KK OCF Margin % Related Terms
Healios KK OCF Margin % Historical Data
* Premium members only.
The historical data trend for Healios KK's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HLOSF vs VRTX, REGN, ALNY: OCF Margin % Comparison
For the Biotechnology subindustry, Healios KK's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healios KK OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Healios KK's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Healios KK's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Healios KK (HLOSF) has a OCF Margin % of -16,006.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Healios KK and its competitors. According to the industry distribution chart, Healios KK ranks #870 out of 957 companies in the Biotechnology industry, placing it in the top 90.9%.
Is Healios KK's OCF Margin % too high?
Healios KK's current OCF Margin % is -16,006.00%. Based on the distribution chart, Healios KK ranks #870 out of 957 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Healios KK has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Healios KK's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Healios KK ranks #870 out of 957 companies for OCF Margin %. This places Healios KK in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Healios KK and its competitors. Healios KK's current OCF Margin % is -16,006.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healios KK stock overvalued right now?
Based on GuruFocus' analysis, Healios KK (HLOSF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.42, compared to a current price of $1.80 — trading 328.6% above its estimated fair value. The current OCF Margin % is -16,006.00%. Healios KK's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Healios KK (HLOSF), the current OCF Margin % is -16,006.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healios KK (HLOSF) Overvalued in 2026?
Based on GuruFocus' analysis, Healios KK stock appears to be overvalued.
The current stock price of $1.80 is trading 328.6% above its estimated GF Value™ of $0.42.
GuruFocus considers Healios KK to be Significantly Overvalued.
Key valuation signals for HLOSF:
OCF Margin %: -16,006.00%
GF Value™: $0.42 vs. price of $1.80 (328.6% above fair value)
No single metric tells the full story. See the HLOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome.
57GF Score
Get the complete analysis for HLOSF
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HLOSF has been successfully added to your 
